Chemistry of carbon compounds – Miscellaneous organic carbon compounds – C-metal
Patent
1981-09-16
1984-04-03
Phillips, Delbert R.
Chemistry of carbon compounds
Miscellaneous organic carbon compounds
C-metal
435 13, C07C10352, C12Q 156
Patent
active
044406789
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to tripeptide derivatives which are very easily split by certain enzymes of the enzyme class 3.4.21., more particularly factor Xa. Therefore, the new tripeptide derivatives are intended to be used as substrates for quantitatively assaying the said enzymes, more particularly factor Xa.
BACKGROUND ART
Factor Xa is a proteolytic enzyme which is formed in the blood coagulation cascade by activation of the proenzyme factor X and which, together with phospholipid and calcium ions, proteolytically splits factor II (prothrombin) at two points of the peptide chain and converts the said factor into factor IIa (thrombin) which finally causes coagulation. In certain pathological disorders, e.g. liver diseases, vitamin deficiency, etc., and in the dicoumarol therapy, the formation of factor X is reduced. In hereditary disturbances in the synthesis of factor X the formation of factor Xa, of course, also reduced correspondingly. Therefore, it is important to have at one's disposal a direct enzymatic assay method which allows factor Xa to be assayed photometrically in blood plasma in a simple and accurate manner.
The main methods for assaying factor Xa are the following: U. Bang, Georg Thieme Verlag, p. 196 (1971)]: Factor X is activated to factor Xa by means of venom of Russel viper and calcium ions. In a one-step operation prothrombin is activated to thrombin by factor Xa in the presence of factor V and phospholipids, and thrombin converts indicator fibrinogen into fibrin. The clotting time is measured. The required factors II and V and fibrinogen are supplied by a substrate which is free from factor X. The clotting time is influenced by the degree of activation of factor X. The activation degree, under otherwise constant conditions, is a function of the concentration of factor X in the sample. This biological method allows no more than a rough assay to be carried out since the clotting time is read off subjectively by the experimentator. Furthermore, manipulated plasma is required during the preparation of which mistakes can occur. Moreover, the fibrinogen which is acting as an indicator is not formed directly, but via activated thrombin (indirect method). Bang, Georg Thieme Verlag, p. 196/7 (171)]: If the factor X preparations to be tested are sufficiently pure, a more accurate assay method can be applied. Esnouf and Williams (1962) have shown that factor Xa has an esterase activity and hence splits synthetic amino acid esters. However, 50 to 100 .mu.g of factor X are required for this assay. On the other hand, lower concentrations of factor Xa can be determined by using carbobenzoxy-phenylalanine p-nitrophenyl ester and measuring the quantity of p-nitrophenol released per time unit. This assaying method has the following disadvantages: The ester used undergoes an autohydrolysis at the applied pH of 8 and, moreover, is not specific for factor Xa since it responds also to many other enzymes. The ester is not soluble in water so that acetone is required. As a result of all these disadvantages this assaying method is inaccurate and costly. tetrapeptide derivatives which are intended to be used as substrates for assaying factor Xa. Bz-Ile-Glu-Gly-Arg-pNA.HCl is disclosed as an example of a tetrapeptide derivative which is split by factor Xa with formation of p-nitroaniline. The formation of p-nitroaniline can be followed spectrophotometrically. This method of assaying factor Xa is somewhat more accurate than the above-described biological and biochemical assaying methods.
However, the tetrapeptide derivatives described in German patent application DE-OS No. 25 52 570 are not sufficiently soluble in aqueous media to allow the assay of factor Xa to be carried out at substrate saturation. In the case where extremely low concentrations of factor Xa have to be determined, e.g. in pathological plasma, the said tetrapeptide derivatives are not sufficiently sensitive to allow reasonably accurate measuring values to be obtained. If the quantity of factor Xa to be measured were incr
REFERENCES:
patent: 3886136 (1975-05-01), Claeson et al.
patent: 4028318 (1977-06-01), Aurell et al.
patent: 4137225 (1982-01-01), Af Ekenstam et al.
patent: 4162941 (1979-07-01), Aurell et al.
patent: 4275153 (1981-06-01), Gargiulo et al.
Pentapharm A.G.
Phillips Delbert R.
LandOfFree
Tripeptide derivatives and their application in assaying enzymes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tripeptide derivatives and their application in assaying enzymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tripeptide derivatives and their application in assaying enzymes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-666508